Society for Neuro-Oncology

ONC201 Shows Clinical Efficacy in H3 K27M-Mutated Diffuse Midline Glioma

Among patients with a performance status of less than 80, 20.6% had an improvement in this metric.

Adding Nivolumab to Standard Care Does Not Improve Survival in Glioblastoma

The median PFS was 10.6 months in the nivolumab group and 10.3 months in the placebo group.

Neuro-Oncology Patient Satisfaction Maintained During COVID-19 Pandemic

Patient satisfaction scores before the pandemic were comparable to scores during the pandemic.